Divestment of Tolmar Australia to international pharmaceutical group Mundipharma.

Henslow advised the global group on the sale of its Australian arm, Tolmar Australia Pty Limited (Tolmar), a specialised uro-oncology company, to international network Mundipharma.

A company with an earned reputation for performance and innovation.

Tolmar International Limited is a global pharmaceuticals group focused on the development, approval, and commercialisation of speciality pharmaceutical products. For Mundipharma, the deal added to the business's global network of associated independent companies engaged in research, development, production and marketing of prescription medicines and consumer healthcare products.

The Highlights

  • Undisclosed

    Deal Value

  • Cash

    Sell-side divestment

  • 8

    International Bidders

Acquisition of an Australian business to a global player

Henslow ran a competitive sale process, managing interest from a broad range of global pharmaceutical companies, resulting in a successful outcome for Tolmar International. This transaction demonstrated our team's international M&A capabilities, acting for a client based in the Americas and dealing with bidder interest from eight countries. The divestment of Tolmar Australia added to our experience and expertise within the pharmaceutical industry including an established list of past clients such as Sigma Pharmaceuticals, Arrow Pharmaceuticals, Healthscope, Sinapse, and Paragon Care.

Tolmar products are an excellent fit for Mundipharma, and we are looking forward to this next stage for our company.

Jane Orr Managing Director of Mundipharma Australia and New Zealand